Physician profile
Robert Cykiert
NPI 1407865538
$121,905.83
in general payments reported to CMS, 2019-2025
18 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $11K · 2021: $6,640 · 2022: $6,967 · 2023: $15K · 2024: $19K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Travel and Lodging: $8,689 · Food and Beverage: $3,110 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,340.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,490.00 |
| Travel and Lodging | $8,688.85 |
| Food and Beverage | $3,109.58 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $111,515.05 | 2019-2025 | Cequa, Xelpros |
| Shire North American Group INC | $7,221.24 | 2019 | |
| Ocular Therapeutix, INC. | $1,181.00 | 2019-2020 | |
| Alcon Vision LLC | $475.22 | 2022-2025 | Clareon Panoptix Pro, Clareon, Tryptyr |
| Abbvie INC. | $294.96 | 2023-2025 | Xen Glaucoma Treatment System |
| Glaukos Corporation | $256.40 | 2023 | Radius Xr |
| Allergan, INC. | $230.05 | 2019-2022 | |
| Sight Sciences, INC. | $226.41 | 2019-2022 | |
| Thea Pharma INC. | $101.03 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $93.89 | 2019 | |
| Amgen INC. | $88.11 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $81.44 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Eyevance Pharmaceuticals LLC | $42.75 | 2019-2020 | |
| Akorn, INC. | $22.54 | 2019 | |
| Kala Pharmaceuticals, INC. | $21.78 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.04 | 2021 | |
| Akorn Operating Company LLC | $18.75 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $15.17 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cykiert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.